GlassScriptPhysician profile
Sakinah Shaw
NPI 1437856820
$7,640.99
in general payments reported to CMS, 2019-2025
14 companies · $5,414 in 2025
The $5,414 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $713 · 2024: $1,514 · 2025: $5,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,269 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Education: $223 · Travel and Lodging: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,268.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Education | $222.98 |
| Travel and Lodging | $149.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,125.71 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $1,115.93 | 2024-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $1,041.23 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $446.82 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $383.48 | 2024-2025 | Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $109.50 | 2025 | Cobenfy |
| Lundbeck LLC | $101.45 | 2024-2025 | Rexulti |
| Alkermes, INC. | $99.04 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $80.63 | 2025 | Fanapt, Hetlioz |
| Indivior INC. | $48.41 | 2024-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $24.06 | 2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $23.69 | 2025 | Auvelity |
| Braeburn INC. | $23.43 | 2024 | Brixadi |
| Neurocrine Biosciences, INC. | $17.61 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sakinah Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.